Compile Data Set for Download or QSAR
Report error Found 60 Enz. Inhib. hit(s) with all data for entry = 10782
TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568474(US11420984, Example 24)
Affinity DataIC50: 3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568474(US11420984, Example 24)
Affinity DataIC50: 10nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM50561038(CHEMBL4752307 | US11420984, Example 7)
Affinity DataIC50: 10nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM50561038(CHEMBL4752307 | US11420984, Example 7)
Affinity DataIC50: 20nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568476(US11420984, Example 26)
Affinity DataIC50: 60nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568478(US11420984, Example 28)
Affinity DataIC50: 90nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568476(US11420984, Example 26)
Affinity DataIC50: 150nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568478(US11420984, Example 28)
Affinity DataIC50: 190nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568467(US11420984, Example 17)
Affinity DataIC50: 200nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568461(US11420984, Example 11)
Affinity DataIC50: 200nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568461(US11420984, Example 11)
Affinity DataIC50: 210nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568469(US11420984, Example 19)
Affinity DataIC50: 220nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568467(US11420984, Example 17)
Affinity DataIC50: 230nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568465(US11420984, Example 15)
Affinity DataIC50: 260nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568464(US11420984, Example 14)
Affinity DataIC50: 260nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568469(US11420984, Example 19)
Affinity DataIC50: 280nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568466(US11420984, Example 16)
Affinity DataIC50: 310nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568466(US11420984, Example 16)
Affinity DataIC50: 310nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568464(US11420984, Example 14)
Affinity DataIC50: 310nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568465(US11420984, Example 15)
Affinity DataIC50: 310nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM50561043(CHEMBL4746323 | US11420984, Example 9)
Affinity DataIC50: 320nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568468(US11420984, Example 18)
Affinity DataIC50: 320nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM50561043(CHEMBL4746323 | US11420984, Example 9)
Affinity DataIC50: 330nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM50561044(CHEMBL4743587 | US11420984, Example 20)
Affinity DataIC50: 340nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568468(US11420984, Example 18)
Affinity DataIC50: 380nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568463(US11420984, Example 13)
Affinity DataIC50: 430nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568471(US11420984, Example 21)
Affinity DataIC50: 480nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM50561044(CHEMBL4743587 | US11420984, Example 20)
Affinity DataIC50: 520nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568458(US11420984, Example 8)
Affinity DataIC50: 560nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568458(US11420984, Example 8)
Affinity DataIC50: 610nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568463(US11420984, Example 13)
Affinity DataIC50: 630nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568471(US11420984, Example 21)
Affinity DataIC50: 680nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568462(US11420984, Example 12)
Affinity DataIC50: 700nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568462(US11420984, Example 12)
Affinity DataIC50: 850nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568472(US11420984, Example 22)
Affinity DataIC50: 930nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM50561039(CHEMBL4749355 | US11420984, Example 23)
Affinity DataIC50: 1.14E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568472(US11420984, Example 22)
Affinity DataIC50: 1.32E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568480(US11420984, Example 30)
Affinity DataIC50: 1.35E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568477(US11420984, Example 27)
Affinity DataIC50: 1.43E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM50561039(CHEMBL4749355 | US11420984, Example 23)
Affinity DataIC50: 2.12E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568480(US11420984, Example 30)
Affinity DataIC50: 2.42E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568477(US11420984, Example 27)
Affinity DataIC50: 3.32E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568460(US11420984, Example 10)
Affinity DataIC50: 3.77E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568456(US11420984, Example 6)
Affinity DataIC50: 3.96E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568453(US11420984, Example 3)
Affinity DataIC50: 4.55E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568460(US11420984, Example 10)
Affinity DataIC50: 4.77E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM568479(US11420984, Example 29)
Affinity DataIC50: 5.27E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-1(Human)
Astrazeneca

US Patent
LigandPNGBDBM50561038(CHEMBL4752307 | US11420984, Example 7)
Affinity DataIC50: 6.41E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568479(US11420984, Example 29)
Affinity DataIC50: 9.28E+3nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetArginase-2, mitochondrial(Human)
Astrazeneca

US Patent
LigandPNGBDBM568453(US11420984, Example 3)
Affinity DataIC50: 1.04E+4nMAssay Description:The inhibitory effects of Examples 1 to 30 on the activity of Human Arginase 1 and Arginase 2 activity were quantified by measuring the formation of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

Displayed 1 to 50 (of 60 total ) | Next | Last >>
Jump to: